Delving into the Latest Updates on Rentschler Biotechnologie Beteiligungs GmbH with Synapse

概览

关联

1

项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的药物

Degarelix Acetate

醋酸地加瑞克

靶点

GnRHR

作用机制

GnRHR拮抗剂

在研机构

Ferring Pharmaceuticals A/S [+5]

原研机构

Ferring BV

在研适应症

去势敏感前列腺癌 [+5]

非在研适应症

晚期前列腺癌 [+6]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2008-12-24

2

项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的临床试验

CTR20140115 / Completed临床3期

比较地加瑞克和戈舍瑞林的有效性和安全性的试验后实施的关于地加瑞克的扩展长期安全性和耐受性试验

评价地加瑞克一个月给药方案对于中国前列腺癌患者在长期治疗过程中的安全性和耐受性

开始日期2014-01-17

申办/合作机构

Ferring Pharmaceuticals A/S

[+3]

CTR20140109 / Completed临床3期

一项开放性、多中心、随机、平行对照的研究，比较地加瑞克与戈舍瑞林对前列腺癌患者的有效性与安全性

验证地加瑞克(240/80mg)每月一次给药方案和戈舍瑞林相比，首次用药后第2天起至第364 天止降低并维持睾酮于去势水平(≤0.5 ng/mL)的非劣性

开始日期2013-01-12

申办/合作机构

Ferring Pharmaceuticals A/S

[+3]

100 项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的临床结果

登录后查看更多信息

0 项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的专利（医药）

登录后查看更多信息

12

项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的文献（医药）

2020-07-01·Drug Research

Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta

Article

作者: von Eick, Harald ; Brzoska, Josef ; Hündgen, Manfred

AbstractThe pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 µg for 3–5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly.

2018-05-04·OncoImmunology2区 · 医学

Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages

2区 · 医学

ArticleOA

作者: Kuhlencord, Meike ; Ludwig, Stephan ; Roth, Johannes ; Köther, Katharina ; Masemann, Dörthe ; Lichty, Brian Dennis ; Wixler, Viktor ; Rapp, Ulf Rüdiger ; Varga, Georg

Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer and demonstrates high resistance to radiation and chemotherapy. These tumors evade immune system detection by promoting an immunosuppressive tumor microenvironment. Genetic analysis has revealed oncogenic activation of the Ras/Raf/MEK/ERK signaling pathway to be a hallmark of NSCLCs, which promotes influenza A virus (IAV) infection and replication in these cells. Thus, we aimed to unravel the oncolytic properties of IAV infection against NSCLCs in an immunocompetent model in vivo. Using Raf-BxB transgenic mice that spontaneously develop NSCLCs, we demonstrated that infection with low-pathogenic IAV leads to rapid and efficient oncolysis, eliminating 70% of the initial tumor mass. Interestingly, IAV infection of Raf-BxB mice caused a functional reversion of immunosuppressed tumor-associated lung macrophages into a M1-like pro-inflammatory active phenotype that additionally supported virus-induced oncolysis of cancer cells. Altogether, our data demonstrate for the first time in an immunocompetent in vivo model that oncolytic IAV infection is capable of restoring and redirecting immune cell functions within the tumor microenvironment of NSCLCs.

2016-12-01·Biotechnology Letters4区 · 工程技术

A simple method to determine IgG light chain to heavy chain polypeptide ratios expressed by CHO cells

4区 · 工程技术

Article

作者: Gerster, Anja ; Krause, Felix ; Müller, Dethardt ; Wodarczyk, Claas ; Köhler, Janet ; Schulze, Andreas ; Reichenbächer, Britta

OBJECTIVESTo establish a high-throughput method for determination of antibodies intra- and extracellular light chain (LC) to heavy chain (HC) polypeptide ratio as screening parameter during cell line development.RESULTSChinese Hamster Ovary (CHO) TurboCell pools containing different designed vectors supposed to result in different LC:HC polypeptide ratios were generated by targeted integration. Cell culture supernatants and cell lysates of a fed batch experiment were purified by combined Protein A and anti-kappa affinity batch purification in 96-well format. Capture of all antibodies and their fragments allowed the determination of the intra- and extracellular LC:HC peptide ratios by reduced SDS capillary electrophoresis. Results demonstrate that the method is suitable to show the significant impact of the vector design on the intra- and extracellular LC:HC polypeptide ratios.CONCLUSIONDetermination of LC:HC polypeptide ratios can give important information in vector design optimization leading to CHO cell lines with optimized antibody assembly and preferred product quality.

100 项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的药物交易

登录后查看更多信息

100 项与 Rentschler Biotechnologie Beteiligungs GmbH 相关的转化医学

登录后查看更多信息